GILD is down slightly on today’s POSITRON data, but that’s not surprising, IMO. The phase-3 results in genotype-2/3 were not better than expected, and a lot of value is already baked into GILD’s share price for the HCV program.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”